Speciality: Rheumatology
Description:
.A warm welcome to all the medical professionals in this interesting session on updates on the treatment strategies of RA and JIA.
Recent updates in the treatment strategies of Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis (JIA) have emphasized a shift towards personalized and targeted therapies. Advances in biological agents, such as TNF inhibitors and interleukin blockers, have revolutionized the management of RA, offering improved disease control and reduced joint damage.
Moreover, the integration of traditional disease-modifying antirheumatic drugs (DMARDs) with biologic therapies has shown promising outcomes in achieving remission and enhancing patients' quality of life. Similarly, in JIA, the advent of biologic agents tailored to specific disease subtypes has led to better disease control and reduced disability in pediatric patients. Early initiation of aggressive treatment strategies, including combination therapy and tight disease monitoring, remains paramount in optimizing outcomes for both RA and JIA patients.
Therefore, get an overall knowledge from this interesting session on the updates of treatment strategies of RA and JIA. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Doctors say lung cancer is still the deadliest cancer, but hope is growing
2.
Child Death Rates Are Rising in the U. s. ; Water Beads Warning; Cancer Studies Retracted.
3.
FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.
4.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
5.
Virtual Reality Travel Reduces Cancer Pain.
1.
Clinical Decision-Making in Oligometastatic Cancer: A Case-Based Perspective
2.
Iron Homeostasis Throughout the Female Lifespan
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
5.
Exercise Rehabilitation in Hematologic Disease Survivorship
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation